MYR GMBH
MYR Pharmaceuticals is focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D virus infections. MYRโs lead compound bulevirtide (Myrcludex), a first-in-class entry inhibitor for the treatment of chronic hepatitis B and D infections, progresses into a phase III clinical study for the indication of chronic HDV infection. The drug candidate has received Orphan Drug Designations for the treatment of HDV infection from the European Medicine... s Agency (EMA) and from the U.S. Food & Drug Administration (FDA). In addition, the EMA has granted PRIority MEdicines (PRIME) scheme eligibility. In parallel the FDA has granted Breakthrough Therapy designation. The British Medicines and Healthcare products Regulatory Agency (MHRA) has recently issued the Promising Innovative Medicine (PIM) designation for MYRโs lead compound Bulevirtide. In addition to hepatitis, bulevirtide has a potential for the treatment of a variety of inflammatory and metabolic diseases via additional pharmacological effects of NTCP inhibition. MYR Pharmaceuticals and its collaborators have obtained encouraging preclinical data that support further development of bulevirtide to treat dyslipidemia, nonalcoholic steatohepatitis (NASH), and primary biliary cholangitis (PBC). A Phase 1 clinical trial for dyslipidemia has been initiated. MYR Pharmaceuticals is headquartered in Bad Homburg (Germany). The company started its operations in 2011 and has raised more than EUR 30 million from a number of venture capital investors - including the German High-Tech Grรผnderfonds - and private investors. The technology was originally developed at the University of Heidelberg (Germany) by Prof. Dr. Stephan Urban and INSERM (France) by Prof. Dr. Phillipe Gripon and represents one the most clinically advanced novel approaches for the treatment of hepatitis B and D.
MYR GMBH
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2011-01-01
Address:
Bad Homburg, Hessen, Germany
Country:
Germany
Website Url:
http://www.myr-pharma.com
Total Employee:
11+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Arlabion
Arlabion is an agri-tech company developing a novel seed treatment to protect crops against fungal infection.
Autodisplay
A biotechnology company commercializing its proprietary expression platform for the display of heterologous proteins or peptide.
Biomedal
Biomedal is a biotech company developing and commercialising technologies, services and products for research, bioindustry and diagnostics.
Biosearch Life
e is a biotechnology company that develops and manufactures products through the innovation of natural ingredients.
Biotrem
Biotrem is a technology company developing an innovative production process of bio-based tableware and packaging.
Cardiola
Cardiola is a biotechnology company developing therapeutic systems for the treatment of chronic heart failure.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Excaliard Pharmaceuticals
Excaliard is a biotechnology company developing antisense drugs for the local treatment of scarring and other fibrotic diseases.
GoDx
GoDx is a biotechnology research center, developing a simple diagnostic test for the detection of infectious pathogens.
Kiro Robotics
Kiro Robotics is a technology company that specializes in the automation of machinery for the hospital sector.
Lactobio
Lactobio is a probiotic and microbiome company developing cosmeceuticals, dietary supplements, and live biotherapeutic products.
MRC-Holland
MRC Holland is a biotechnology company specialized in the production of assays for gene copy number and gene variant detection.
Syntaxin
Syntaxin engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases.
Xiomateria
Xiomateria has develops biomaterials that assist in the treatment of diseases and infections.